-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DYi1coIrHT6TzJdGJDFkURH6SK67IkJVmfpbempevaXlbK4sakh5Ei3eyacrbd19 2fJIyWVDFPKjsCgSnV0wtA== 0001209191-06-012297.txt : 20060222 0001209191-06-012297.hdr.sgml : 20060222 20060222134318 ACCESSION NUMBER: 0001209191-06-012297 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060221 FILED AS OF DATE: 20060222 DATE AS OF CHANGE: 20060222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RENTON HOLLINGS CENTRAL INDEX KEY: 0001187333 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 06635599 BUSINESS ADDRESS: STREET 1: ONYX PHARMACEUTICALS STREET 2: 3031 RESEARCH DRIVE CITY: RICHMOND STATE: CA ZIP: 94806 BUSINESS PHONE: 5102628769 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5105976500 MAIL ADDRESS: STREET 1: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 4 1 doc4.xml FORM 4 SUBMISSION X0202 4 2006-02-21 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001187333 RENTON HOLLINGS C/O ONYX PHARMACEUTICALS, INC. 2100 POWELL ST., 12TH FLOOR EMERYVILLE CA 94608 1 1 0 0 President and CEO Common Stock 2006-02-21 4 M 0 2500 4.18 A 22748 I Family Trust Common Stock 2006-02-21 4 S 0 2500 27.77 D 20248 I Family Trust Stock Option (Right to Buy) 4.18 2006-02-21 4 M 0 2500 0.00 D 2012-08-12 Common Stock 2500 110000 D Reporting person is deemed to beneficially own an addtional (i) 1,200 shares held by his spouse and (ii) 10,737 shares held by him directly. The shares subject to the grant are immediately exercisable upon grant but are subject to the following vesting schedule: 12.5% of the shares subject to the option vest 6 months following the date of grant. The remaining shares vest in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. /s/ Marilyn E. Wortzman, Attorney-in-fact 2006-02-21 -----END PRIVACY-ENHANCED MESSAGE-----